10x Genomics Corp - TXG Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization
The profitability of 10x Genomics, Inc. (TXG) is based on the sale of expensive cell analysis systems and high-margin reagents. The change in the EV/EBITDA multiple clearly demonstrates the business valuation dynamics, where 0.00 represents the latest level. The company is currently optimizing its model to grow profits from consumables by developing spatial biology methods through partnerships with scientific laboratories.
Summary analytical data breakdowns for 10xgenomics.com (TXG)
- market price and analyst price targets:
- issuer market value details:
- book value of equity indicators:
- debt and liquidity data:
- business earnings and investment ratios data:
TXG - Company Profit|Projected Future Earnings 10x Genomics, Inc.|TXG - Price to Earnings Ratio|Projected Price to Earnings 10x Genomics, Inc.|TXG - Growth-Adjusted Market Cap to Net Income|Enterprise Value to EBITDA Ratio 10x|TXG - Company profit before taxes, interest and amortization|Net earnings per share for the last 12 months 10x Genomics|TXG - Earnings per share for the last 12 months|Quarterly EPS earnings growth 10xgenomics.com|TXG - Net earnings per share change in current year|Earnings growth forecast for next year 10x Genomics, Inc.
Comprehensive company analysis:10x Genomics Corp (TXG)
Professional selection of resilient assets is based on an analysis of the ratio of total enterprise value, including net debt, to earnings before interest, taxes, depreciation, and amortization. The EV/EBITDA trajectory of 10x Genomics, Inc. (TXG) reflects market expectations for revenue scaling from the supply of equipment and reagents for molecular research, confirming the fundamental value of 10x Genomics, Inc. technologies within the oncology and neurobiology segments.
Key competitors
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization tempus.com TEM|QGEN: Enterprise Value to Operating Income Before Depreciation|IONS - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA repligen.com|Avidity Biosciences, Inc. (RNA) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio CRISPR Therapeutics Inc|WGS (Sema4) - EV/EBITDA Multiple|Ultragenyx Corp (RARE) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple BEAM|Enterprise Value to EBITDA Ratio sarepta.com SRPT|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Twist Bioscience, Inc. TWST|Total Company Value to Operating Income Before Depreciation Ratio Intellia Therapeutics Inc (NTLA)|STOK: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation BLFS (BioLife)|WVE: EV/EBITDA Multiple|MAZE - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Sionna Therapeutics|Enterprise Value to Operating Income Before Depreciation PRME (Prime Medicine Inc)|EV/EBITDA Multiple TSHA|Enterprise Value to EBITDA Ratio uniQure Pharma QURE|MeiraGTx Holdings plc - Enterprise Value to EBITDA Ratio|Total Company Value to Operating Income Before Depreciation Ratio regenxbio.com (RGNX)|SLDB: Enterprise Value to EBITDA Ratio|Ocugen Inc - Enterprise Value to Operating Income Before Depreciation Ratio|PACB (Pacific Biosciences of California) - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation BNTC|DSGN (Design Therapeutics) - EV/EBITDA Multiple|RCKT - Enterprise Value to EBITDA Multiple|EV/EBITDA Multiple FDMT|lexeotx.com - Enterprise Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Korro Bio KRRO|EDIT: Enterprise Value to Operating Income Before Depreciation|Silence Therapeutics - EV/EBITDA Multiple|PRQR - EV/EBITDA Multiple|CDXS: EV/EBITDA Multiple|SGMO: Enterprise Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio NAUT|Enterprise Value to Operating Income Before Depreciation MGX (Metagenomi Therapeutics)|Enterprise Value to EBITDA Ratio DTIL (Precision BioSciences)|GBIO (generationbio.com) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple BOLD (Boundless Bio)|Enterprise Value to EBITDA Multiple Exicure Inc.|Celsion Corporation - EV/EBITDA Multiple|Company Value to EBITDA Phio Pharmaceuticals|mustangbio.com (MBIO) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation RNAZ|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Bionano Genomics Inc.|Company Value to EBITDA Applied DNA Sciences Inc APDN|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Bluebird Bio (BLUE)|Enterprise Value to EBITDA Ratio immunoprecise.com IPA|EV/EBITDA Multiple OMGA (Omega Therapeutics)|Total Company Value to Operating Income Before Depreciation Ratio singulargenomics.com (OMIC)|Regulus Therapeutics Inc. - EV/EBITDA Multiple|Syros Pharmaceuticals Inc. (SYRS) - Enterprise Value to EBITDA Ratio|Codex DNA (TBIO) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|TCON - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio UBX
